TY - JOUR
T1 - Managing Chemotherapy-Related Cardiotoxicity in Survivors of Childhood Cancers
AU - Lipshultz, Steven E.
AU - Diamond, Melissa B.
AU - Franco, Vivian I.
AU - Aggarwal, Sanjeev
AU - Leger, Kasey
AU - Santos, Maria Verônica
AU - Sallan, Stephen E.
AU - Chow, Eric J.
N1 - Funding Information:
Acknowledgements The authors have no conflicts of interest that are directly relevant to the content of this review. Eric Chow is supported by grants from the National Cancer Institute (K07 CA151775), the Leukemia and Lymphoma Society, and the St. Baldricks’ Foundation.
Publisher Copyright:
© 2014, Springer International Publishing Switzerland.
PY - 2014/10
Y1 - 2014/10
N2 - In the US, children diagnosed with cancer are living longer, but not without consequences from the same drugs that cured their cancer. In these patients, cardiovascular disease is the leading cause of non-cancer-related morbidity and mortality. Although this review focuses on anthracycline-related cardiomyopathy in childhood cancer survivors, the global lifetime risk of other cardiovascular diseases such as atherosclerosis, arrhythmias and intracardiac conduction abnormalities, hypertension, and stroke also are increased. Besides anthracyclines, newer molecularly targeted agents, such as vascular endothelial growth factor receptor and tyrosine kinase inhibitors, also have been associated with acute hypertension, cardiomyopathy, and increased risk of ischemic cardiac events and arrhythmias, and are summarized here. This review also covers other risk factors for chemotherapy-related cardiotoxicity (including both modifiable and non-modifiable factors), monitoring strategies (including both blood and imaging-based biomarkers) during and following cancer treatment, and discusses the management of cardiotoxicity (including prevention strategies such as cardioprotection by use of dexrazoxane).
AB - In the US, children diagnosed with cancer are living longer, but not without consequences from the same drugs that cured their cancer. In these patients, cardiovascular disease is the leading cause of non-cancer-related morbidity and mortality. Although this review focuses on anthracycline-related cardiomyopathy in childhood cancer survivors, the global lifetime risk of other cardiovascular diseases such as atherosclerosis, arrhythmias and intracardiac conduction abnormalities, hypertension, and stroke also are increased. Besides anthracyclines, newer molecularly targeted agents, such as vascular endothelial growth factor receptor and tyrosine kinase inhibitors, also have been associated with acute hypertension, cardiomyopathy, and increased risk of ischemic cardiac events and arrhythmias, and are summarized here. This review also covers other risk factors for chemotherapy-related cardiotoxicity (including both modifiable and non-modifiable factors), monitoring strategies (including both blood and imaging-based biomarkers) during and following cancer treatment, and discusses the management of cardiotoxicity (including prevention strategies such as cardioprotection by use of dexrazoxane).
UR - http://www.scopus.com/inward/record.url?scp=84919905150&partnerID=8YFLogxK
U2 - 10.1007/s40272-014-0085-1
DO - 10.1007/s40272-014-0085-1
M3 - Review article
C2 - 25134924
AN - SCOPUS:84919905150
VL - 16
SP - 373
EP - 389
JO - Pediatric Drugs
JF - Pediatric Drugs
SN - 1174-5878
IS - 5
ER -